MT Newswires31m agoneutral
European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday TradingEuropean equities traded in the US as American depositary receipts were edging higher late Wednesday
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
527last 24h
2508last 7d
482● bullish (7d)
256● bearish (7d)
197publishers
Moby37m agoneutral
Novo Nordisk Swallows the Bitter PillThe Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline stumble.
Yahoo Finance Video41m agoneutralVIDEO
Eli Lilly is treating nearly 10% of US obesity population with GLP-1s: CFOAfter the company reported second quarter earnings and raised its full-year sales guidance, Eli Lilly (LLY) CFO Lucas Montarce outlines the expansion opportunities that the pharmaceutical giant is seeing in its GLP-1 category, specifically the introduction of oral weight-loss drugs to the market.
Simply Wall St.1h agoneutral
Novo Nordisk (CPSE:NOVO B) Stock Still Looks Like A Bargain As Shares Fell 48%Novo Nordisk stock has given investors a mixed ride, with solid 1 year gains but a sharp decline over 3 years, even as the broader valuation checks still suggest the shares lean cheap compared with fundamentals. Recent news on blockbuster diabetes and obesity drugs on one side and a failed late stage cardiovascular trial on the other keeps the market focused on what price fairly reflects this balance. Over the past 3 years the share price is down 48.1%, which means long term holders are...
The Wall Street Journal2h agoneutral
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative DealsChief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Reuters Videos2h agoneutralVIDEO
Novo Nordisk looks to future proof as investors worry over pipeline<body><p>STORY: :: Novo Nordisk</p><p>'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.''</p><p>:: How is Novo Nordisk future proofing as investors worry about pipeline?</p><p>:: August 5, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent </p><p>''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. ''</p><p>'''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.''</p><p>:: What is CEO Mike Doutsdar's response?</p><p>:: Novo Nordisk</p><p>''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development. And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''</p></body>
InvestorsHub6h agoneutral
Middle East optimism lifts sentiment as SpaceX and AMD earnings dominate attention: Dow Jones, S&P, Nasdaq, Wall Street FuturesUS stock futures edged higher on Wednesday as investors reacted to renewed hopes of easing tensions in the Middle East, while corporate earnings from SpaceX (NASDAQ:SPCX), Advanced Micro Devices (NASDAQ:AMD) and Novo Nordisk (NYSE:NVO) drove significant pre-market trading. Although geopolitical developments supported overall market sentiment, investors also assessed company-specific news, particularly Elon Musk’s latest comments, which weighed on both SpaceX and AMD shares.
Simply Wall St.20h agoneutral
Novo Nordisk (CPSE:NOVO B) Reports Mixed ZEUS Phase 3 Results For ZiltivekimabNovo Nordisk has reported headline phase 3 results from the ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The study met key biomarker endpoints but did not reduce major adverse cardiovascular events compared with placebo. The outcome affects Novo Nordisk’s cardiovascular pipeline focus and is expected to trigger a non cash impairment in the upcoming quarter. The ZEUS readout lands at a sensitive time for Novo...
Barrons.com21h agoneutral
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.
The Wall Street Journal22h agoneutral
Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter BoostThe Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.
The Wall Street Journal1d agoneutral
SpaceX Earnings, Jobs Numbers: What to Watch This WeekToday Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
Financial Times1d agoneutral
‘Arrogance kills’: Novo chief injects risk-taking into Ozempic makerOne year since becoming Novo Nordisk’s chief executive, Mike Doustdar is betting on the “phenomenal” sales of its weight-loss pill, new drugs...
Zacks2d agoneutral
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Zacks2d agoneutral
Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.
IPO-Edge.com2d agoneutral
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles HarrisonIPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]
Simply Wall St.2d agoneutral
Eli Lilly (LLY) Stock Looks Below Fair Value On Cash FlowEli Lilly stock has delivered very strong gains over the past five years, yet the latest valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a sizeable gap below the current price while the broader scorecard still leans expensive. Eli Lilly has returned about 357.2% over five years, which puts extra focus on whether the current price already reflects investors' optimism. The FDA's Breakthrough Therapy designation for olomorasib can...
Zacks2d agoneutral
Bear of the Day: Boston Beer (SAM)With American alcohol consumption near historic lows, Boston Beer Company is fighting an uphill battle.
The Wall Street Journal2d agoneutral
Jobs Numbers, SpaceX Earnings: What to Watch This WeekThe monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.
TheStreet2d agoneutral
Novo Nordisk shares in hot water after disappointing trialInvestors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...
Simply Wall St.3d agoneutral
Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap?Trial setback puts focus on Novo Nordisk stock Novo Nordisk (NYSE:NVO) is under fresh scrutiny after the ZEUS phase 3 trial for heart drug candidate ziltivekimab failed to reduce major adverse cardiovascular events versus placebo, prompting a share price drop. See our latest analysis for Novo Nordisk. The ZEUS result comes after a tougher start to the year for Novo Nordisk, with the share price down 10.14% year to date and the latest 1 day move falling 8.78%. However, the 90 day share price...
Simply Wall St.3d agoneutral
Novo Nordisk (NVO) Stock Looks Below Fair Value Despite Recent SetbacksNovo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which sets up a different picture from what the share price alone might suggest. Recent headlines around the ZEUS trial setback and legal action against Eli Lilly have sharpened the focus on whether the current price fairly reflects the risks and opportunities. The share price decline of 36.4% over three years points to a period where investors who bought...
Stocktwits4d agoneutral
NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To CourtThe Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.
Stocktwits4d agoneutral
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.
Motley Fool4d agoneutral
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?With the stock near a 5-year low, is it worth a look?
InvestorsHub4d agoneutral
Novo Nordisk stock sinks 9% as heart drug fails trialKey takeawaysNovo Nordisk’s U. S.
Barchart4d agoneutral
NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage TrialNovo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.
MT Newswires4d agoneutral
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage TrialNovo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri
MT Newswires4d agoneutral
European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in TrialEuropean stock markets closed mixed in Friday trading with the Stoxx 600 easing 0.1%, Germany's DAX
Barrons.com5d agoneutral
Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage TrialThe Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.